Advertisement

Topics

Search Results for "Tace Treatment Parameters Doxorubicin"

05:32 EDT 18th October 2017 | BioPortfolio

Original Source: Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking the blood flow to the tumor. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether transarteri...

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Early Embryo Viability Assessment Test (Eeva)

Auxogyn’s non-invasive Early Embryo Viability Assessment Test (Eeva) may improve in vitro fertilization (IVF) outcomes by providing IVF clinics and patients with objective information on embry...

Pediculosis - louse (lice) treatment

   To view our most recent articles on Lice Treatment please go to: http://www.bioportfolio.com/news/article/987636/Pediculosis-Louse-Lice-Treatment.html    

Specific treatment

Dysrhythmia Treatment

Matching News

Gene Signature Predictive of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization (TACE)

Hepatocellular Carcinoma (HCC) is one of the most common cancers worldwide with largely unfavorable outcomes due to a lack of effective treatment options for patients in the later state of disease. Th...

[Articles] Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

The addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival compared with single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic ...

[Articles] Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Doxorubicin should remain the standard first-line treatment for most patients with advanced soft-tissue sarcoma. These results provide evidence for clinicians to consider with their patients when sele...

Global and Chinese Doxorubicin hcl Industry, 2017 Market Research Report [Updated: 21062017] Prices from USD $3000

The 'Global and Chinese Doxorubicin hcl Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Doxorubicin hcl industry with a focus on the C...

Global and Chinese Doxorubicin hcl Industry, 2017 Market Research Report [Report Updated: 21062017] Prices from USD $3000

The 'Global and Chinese Doxorubicin hcl Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Doxorubicin hcl industry with a focus on the C...

First-line Doxorubicin for Advanced Sarcoma, Not Combo?

Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination. Medscape Medical News

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma

Mentice Aims to Reduce TACE Procedure Times, Minimize Radiation with New TACE Simulation Training Solution

Mentice, the world’s leading endovascular simulation solution provider, has announced the release of a new simulation training software for transarterial chemoembolization (TACE...

Matching PubMed Articles

Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.

The aim of the present study was to compare the effectiveness of transarterial chemoembolization (TACE), TACE combined with Jie-du granules (JD), and TACE combined with sorafenib (SOR) for treating pa...

Effect of transcatheter arterial chemoembolization combined with thymosin alpha 1 on the autophagy of immune cells from advanced hepatocellular carcinoma.

Objective: To investigate the effect of transcatheter arterial chemoembolization(TACE)combined with thymosin alpha1(Tα1)on the autophagy of immune cells from advanced hepatocellular carcinoma. Method...

Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.

This study was designed to compare the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with apatinib and TACE alone in the treatment of intermediate and advanc...

Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy.

BACKGROUND The aim of this study was to evaluate the safety and efficacy of DSM (degradable starch microspheres) as an embolic agent in transarterial chemoembolization in the treatment of intrahepatic...

Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.

Transcatheter arterial chemoembolization (TACE) is the first-line treatment for intermediate stage hepatocellular carcinoma (HCC) and prolongs survival in HCC patients. However, repeated TACE results ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement